The evolution of personalized medicine: literature review
https://doi.org/10.17709/2410-1893-2022-9-3-9
Abstract
"Personalized" medicine is based on the belief that each person has unique molecular, physiological, environmental and behavioral characteristics and in case of disease development each patient should be treated taking into account these unique characteristics. This belief was to somehow confirmed by the use of the latest technologies, such as DNA sequencing, proteomics, imaging protocols and the use of wireless devices for health monitoring, which revealed inter-individual differences in gene expression and penetrance levels. A search was conducted for literary sources (scientific articles), including those published in peer-reviewed journals indexed in Pubmed, WOS, Scopus and RSCI from 2010 to 2021. The review includes 49 articles on personalized medicine. The technologies that make personalized medicine possible, new experience, methods of testing and prospects for the use of individually selected medicinal preparations, as well as potential approaches to the treatment of people with fertility problems and infertility are considered. It can be assumed that the individualization of medical practice will develop, especially in the case of rare genetic diseases. Moreover, an individual approach to the patient is more effective and rentable.
About the Authors
I. S. Dolgopolov
Tver State Medical University
Russian Federation
Russian Federation
Dr. Sci. (Med.), head of the department of pediatrics, pediatric faculty, head of the pediatric medical center,
12/1 Vorontsovo Pole str., Moscow 105064
M. Yu. Rykov
Tver State Medical University;
N. A. Semashko National Research Institute of Public Health
Russian Federation
Russian Federation
Dr. Sci. (Med.), associate professor, head of the department of Oncology of the Faculty of Additional Professional Education, Advisor to the Rector for Scientific Work, 12/1 Vorontsovo Pole str., Moscow 105064;
researcher, Moscow
References
1. Schork NJ. Personalized medicine: Time for one-person trials. Nature. 2015 Apr 30;520(7549):609–611. https://doi.org/10.1038/520609a
2. Lillie EO, Patay B, Diamant J, Issell B, Topol EJ, Schork NJ. The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Per Med. 2011 Mar;8(2):161–173. https://doi.org/10.2217/pme.11.7
3. Duan N, Kravitz RL, Schmid CH. Single-patient (n-of-1) trials: a pragmatic clinical decision methodology for patient-centered comparative effectiveness research. J Clin Epidemiol. 2013 Aug;66(8 Suppl):S21–8. https://doi.org/10.1016/j.jclinepi.2013.04.006
4. Scuffham PA, Nikles J, Mitchell GK, Yelland MJ, Vine N, Poulos CJ, et al. Using N-of-1 trials to improve patient management and save costs. J Gen Intern Med. 2010 Sep;25(9):906–913. https://doi.org/10.1007/s11606-010-1352-7
5. Daza EJ. Causal Analysis of Self-tracked Time Series Data Using a Counterfactual Framework for N-of-1 Trials. Methods Inf Med. 2018 Feb;57(1):e10–e21. https://doi.org/10.3414/ME16-02-0044
6. Swan M. The Quantified Self: Fundamental Disruption in Big Data Science and Biological Discovery. Big Data. 2013 Jun;1(2):85–99. https://doi.org/10.1089/big.2012.0002
7. Biankin AV, Piantadosi S, Hollingsworth SJ. Patient-centric trials for therapeutic development in precision oncology. Nature. 2015 Oct 15;526(7573):361–70. https://doi.org/10.1038/nature15819
8. Simon R, Roychowdhury S. Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov. 2013 May;12(5):358– 369. https://doi.org/10.1038/nrd3979
9. Chen Y, Elenee Argentinis JD, Weber G. IBM Watson: How cognitive computing can be applied to big data challenges in life sciences research. Clinical Therapeutics. 2016; 38(4):688–701. https://doi.org/10.1016/j.clinthera.2015.12.001
10. Klasnja P, Hekler EB, Shiffman S, Boruvka A, Almirall D, Tewari A, et al. Microrandomized trials: An experimental design for developing just-in-time adaptive interventions. Health Psychol. 2015 Dec;34S:1220–1228. https://doi.org/10.1037/hea0000305
11. Laber EB, Lizotte DJ, Qian M, Pelham WE, Murphy SA. Dynamic treatment regimes: technical challenges and applications. Electron J Stat. 2014;8(1):1225–1272. https://doi.org/10.1214/14-ejs920
12. Chakraborty B, Murphy SA. Dynamic Treatment Regimes. Annu Rev Stat Appl. 2014;1:447–464. https://doi.org/10.1146/annurev-statistics-022513-115553
13. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006 Aug 25;126(4):663–676. https://doi.org/10.1016/j.cell.2006.07.024
14. Beltrao-Braga PCB, Pignatari GC, Russo FB, Fernandes IR, Muotri AR. In-a-dish: induced pluripotent stem cells as a novel model for human diseases. Cytometry A. 2013 Jan;83(1):11–17. https://doi.org/10.1002/cyto.a.22231
15. Sayed N, Liu C, Wu JC. Translation of Human-Induced Pluripotent Stem Cells: From Clinical Trial in a Dish to Precision Medicine. J Am Coll Cardiol. 2016 May 10;67(18):2161–2176. https://doi.org/10.1016/j.jacc.2016.01.083
16. Wu J, Izpisua Belmonte JC. Stem Cells: A Renaissance in Human Biology Research. Cell. 2016 Jun 16;165(7):1572–1585. https://doi.org/10.1016/j.cell.2016.05.043
17. Uppada V, Gokara M, Rasineni GK. Diagnosis and therapy with CRISPR advanced CRISPR based tools for point of care diagnostics and early therapies. Gene. 2018 May 20;656:22–29. https://doi.org/10.1016/j.gene.2018.02.066
18. Ho BX, Pek NMQ, Soh BS. Disease Modeling Using 3D Organoids Derived from Human Induced Pluripotent Stem Cells. Int J Mol Sci. 2018 Mar 21;19(4):936. https://doi.org/10.3390/ijms19040936
19. Aboulkheyr Es H, Montazeri L, Aref AR, Vosough M, Baharvand H. Personalized Cancer Medicine: An Organoid Approach. Trends Biotechnol. 2018 Apr;36(4):358–371. https://doi.org/10.1016/j.tibtech.2017.12.005
20. Crystal AS, Shaw AT, Sequist LV, Friboulet L, Niederst MJ, Lockerman EL, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science. 2014 Dec 19;346(6216):1480–1486. https://doi.org/10.1126/science.1254721
21. Jonas O, Landry HM, Fuller JE, Santini JT, Baselga J, Tepper RI, et al. An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors. Sci Transl Med. 2015 Apr 22;7(284):284ra57. https://doi.org/10.1126/scitranslmed.3010564
22. Klinghoffer RA, Bahrami SB, Hatton BA, Frazier JP, Moreno-Gonzalez A, Strand AD, et al. A technology platform to assess multiple cancer agents simultaneously within a patient’s tumor. Sci Transl Med. 2015 Apr 22;7(284):284ra58. https://doi.org/10.1126/scitranslmed.aaa7489
23. Robinton DA, Daley GQ. The promise of induced pluripotent stem cells in research and therapy. Nature. 2012 Jan 18;481(7381):295– 305. https://doi.org/10.1038/nature10761
24. Appelboom G, Camacho E, Abraham ME, Bruce SS, Dumont EL, Zacharia BE, et al. Smart wearable body sensors for patient self-assessment and monitoring. Arch Public Health. 2014;72(1):28. https://doi.org/10.1186/2049-3258-72-28
25. Swan M. The Quantified Self: Fundamental Disruption in Big Data Science and Biological Discovery. Big Data. 2013 Jun;1(2):85–99. https://doi.org/10.1089/big.2012.0002
26. Schork NJ, Nazor K. Integrated Genomic Medicine: A Paradigm for Rare Diseases and Beyond. Adv Genet. 2017;97:81–113. https://doi.org/10.1016/bs.adgen.2017.06.001
27. Worthey EA, Mayer AN, Syverson GD, Helbling D, Bonacci BB, Decker B, et al. Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genet Med. 2011 Mar;13(3):255–262. https://doi.org/10.1097/GIM.0b013e3182088158
28. Bainbridge MN, Wiszniewski W, Murdock DR, Friedman J, Gonzaga-Jauregui C, Newsham I, et al. Whole-genome sequencing for optimized patient management. Sci Transl Med. 2011 Jun 15;3(87):87re3. https://doi.org/10.1126/scitranslmed.3002243
29. O'Rawe JA, Fang H, Rynearson S, Robison R, Kiruluta ES, Higgins G, et al. Integrating precision medicine in the study and clinical treatment of a severely mentally ill person. PeerJ. 2013;1:e177. https://doi.org/10.7717/peerj.177
30. Wartman LD. A case of me: clinical cancer sequencing and the future of precision medicine. Cold Spring Harb Mol Case Stud. 2015 Oct;1(1):a000349. https://doi.org/10.1101/mcs.a000349
31. Chen R, Mias GI, Li-Pook-Than J, Jiang L, Lam HYK, Chen R, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell. 2012 Mar 16;148(6):1293–1307. https://doi.org/10.1016/j.cell.2012.02.009
32. Forsdyke DR. Summertime dosage-dependent hypersensitivity to an angiotensin II receptor blocker. BMC Res Notes. 2015 Jun 9;8:227. https://doi.org/10.1186/s13104-015-1215-8
33. Schork NJ. Genetic parts to a preventive medicine whole. Genome Med. 2013;5(6):54. https://doi.org/10.1186/gm458
34. Patel CJ, Sivadas A, Tabassum R, Preeprem T, Zhao J, Arafat D, et al. Whole genome sequencing in support of wellness and health maintenance. Genome Med. 2013;5(6):58. https://doi.org/10.1186/gm462
35. Sverdlov O, van Dam J, Hannesdottir K, Thornton-Wells T. Digital Therapeutics: An Integral Component of Digital Innovation in Drug Development. Clin Pharmacol Ther. 2018 Jul;104(1):72–80. https://doi.org/10.1002/cpt.1036
36. Kaner EF, Beyer FR, Garnett C, Crane D, Brown J, Muirhead C, et al. Personalised digital interventions for reducing hazardous and harmful alcohol consumption in community-dwelling populations. Cochrane Database Syst Rev. 2017 Sep 25;9:CD011479. https://doi.org/10.1002/14651858.CD011479.pub2
37. Iacoviello BM, Steinerman JR, Klein DB, Silver TL, Berger AG, Luo SX, et al. Clickotine, A Personalized Smartphone App for Smoking Cessation: Initial Evaluation. JMIR Mhealth Uhealth. 2017 Apr 25;5(4):e56. https://doi.org/10.2196/mhealth.7226
38. Jungheim ES, Carson KR. Leveraging real-world data to move toward more personalized fertility treatment. Fertil Steril. 2018 Apr;109(4):608–609. https://doi.org/10.1016/j.fertnstert.2018.01.036
39. Van Dijk MR, Koster MPH, Willemsen SP, Huijgen NA, Laven JSE, Steegers-Theunissen RPM. Healthy preconception nutrition and lifestyle using personalized mobile health coaching is associated with enhanced pregnancy chance. Reprod Biomed Online. 2017 Oct;35(4):453–460. https://doi.org/10.1016/j.rbmo.2017.06.014
40. Yurttas Beim P, Parfitt DE, Tan L, Sugarman EA, Hu-Seliger T, Clementi C, et al. At the dawn of personalized reproductive medicine: opportunities and challenges with incorporating multigene panel testing into fertility care. J Assist Reprod Genet. 2017 Dec;34(12):1573–1576. https://doi.org/10.1007/s10815-017-1068-2
41. DeAngelis AM, Roy-O’Reilly M, Rodriguez A. Genetic alterations affecting cholesterol metabolism and human fertility. Biol Reprod. 2014 Nov;91(5):117. https://doi.org/10.1095/biolreprod.114.119883
42. Jungheim ES, Meyer MF, Broughton DE. Best practices for controlled ovarian stimulation in in vitro fertilization. Semin Reprod Med. 2015 Mar;33(2):77–82. https://doi.org/10.1055/s-0035-1546424
43. Tao T, Del Valle A. Human oocyte and ovarian tissue cryopreservation and its application. J Assist Reprod Genet. 2008 Jul;25(7):287– 296. https://doi.org/10.1007/s10815-008-9236-z
44. Geel TM, Ruiters MHJ, Cool RH, Halby L, Voshart DC, Andrade Ruiz L, et al. The past and presence of gene targeting: from chemicals and DNA via proteins to RNA. Philos Trans R Soc Lond B Biol Sci. 2018 Jun 5;373(1748):20170077. https://doi.org/10.1098/rstb.2017.0077
45. Nagamatsu G, Hayashi K. Stem cells, in vitro gametogenesis and male fertility. Reproduction. 2017 Dec;154(6):F79–F91. https://doi.org/10.1530/REP-17-0510
Supplementary files
Review
For citations:
Dolgopolov I.S., Rykov M.Yu. The evolution of personalized medicine: literature review. Research and Practical Medicine Journal. 2022;9(3):117-128. (In Russ.) https://doi.org/10.17709/2410-1893-2022-9-3-9
Views:
700
Email this article 